Commentary · 21 Feb 2026
Conference abstractPublished 11 Apr 2022
Prostate cancer biomarker: from bench to clinic
Washington University School of Medicine and Health Sciences, USA
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
There are several prognostic models for predicting overall survival (OS) of patients with metastatic castration-resistant prostate cancer (mCRPC). Circulating tumor cell (CTCs) enumeration at baseline and its conversion post systemic treatment are the most accurate and independent predictor of OS in mCRPC. This talk will cover the biomarker aspect of mCRPC patients CTCs and current research related to its predictive value of CTCs AR-V7 analysis in selecting novel androgen receptor signaling inhibitors, prognostic value of CTC cluster; CTCs heterogeneity and future adaptive therapeutic selection based on single cell CTC genomic and transcriptomes analysis. In the predictive biomarker front, clinical utility of the analysis of AR-V7, DNA damage repair pathway gene, PSMA, tumor mutation burden and MSI status in prostate cancer will be discussed.
Subjects
Oncology & CancerAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Cancer Science & Therapy.
Perspective · 21 Feb 2026
Finding Potential Passerini Adducts for Anticancer Drug Development
Perspective · 21 Feb 2026
Head and Neck Cutaneous Squamous Cell Carcinoma with Perineural Invasion
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalCancer Science & Therapy
- SubjectOncology & Cancer
- BylineArticles whose byline prints “Jianqing Lin”
